Health
Clover Biopharmaceuticals Announces Positive Preclinical Data and Updates on Phase 1 Study for its Adjuvanted S-Trimer COVID-19 Vaccine Candidate – Press Release – Digital Journal
Joshua Liang, Chief Executive Officer of Clover Biopharmaceuticals, said, “We are excited to share these important preclinical results showing that our S-Trimer COVID-19 vaccine candidate induces immune protection against SARS-CoV-2, and we are also pleased w…
CHENGDU, China–(Business Wire)–Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on discovering and developing transformative biologic therapies and vaccines, today announced positive preclinical data demonstrating that its protein-based COVID-19 S-Trimer vaccine candidate in combination with adjuvants from either GSK (London Stock Exchange: GSK) or Dynavax (Nasdaq: DVAX) induces a strong immune response and protection against SARS-CoV-2 in animal models. The man…
-
Noosa News24 hours agoQueen Street Mall to get a 3D digital billboard; Dutton dumps controversial plans to end flexible work; Measles alert for tourist hotspots
-
Noosa News16 hours agoTeenager sentenced to 12 years for ‘heinous’ Acacia Ridge murder
-
Noosa News14 hours agoGirl’s death in a Queensland cult
-
General14 hours agoTeen driver on cocaine racing to Perth nightclub before high-speed crash that killed Nick Campo, court hears